Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Antihypertensive Effects of SGLT2-Inhibitors: Considerations for Clinical Practice

Author(s): Andrea Da Porto*, Luca Bulfone and Leonardo Sechi

Volume 22, Issue 4, 2024

Published on: 18 December, 2023

Page: [231 - 233] Pages: 3

DOI: 10.2174/0115701611274645231208102130

conference banner
Next »
[1]
Wilding JPH, Evans M, Fernando K, et al. The place and value of sodium-glucose cotransporter 2 inhibitors in the evolving treatment paradigm for type 2 diabetes mellitus: A narrative review. Diabetes Ther 2022; 13(5): 847-72.
[http://dx.doi.org/10.1007/s13300-022-01228-w] [PMID: 35307801]
[2]
Scheen AJ. Real-life underuse of SGLT2 inhibitors for patients with type 2 diabetes at high cardiorenal risk. Diabetes Epidemiology and Management 2024; p. 13100184.
[http://dx.doi.org/10.1016/j.deman.2023.100184]
[3]
Kao TW, Huang CC. Pleiotropic effect of sodium-glucose cotransporter 2 inhibitors on blood pressure. Front Cardiovasc Med 2022; 91086672.
[http://dx.doi.org/10.3389/fcvm.2022.1086672] [PMID: 36606275]
[4]
Brosolo G, Da Porto A, Bulfone L. Insulin resistance and high blood pressure: mechanistic insight on the role of the kidney. Biomedicines 2022; 10(10): 2374.
[5]
Brosolo G, Da Porto A, Bulfone L, et al. Plasma lipoprotein(a) levels as determinants of arterial stiffening in hypertension. Biomedicines 2021; 9(11): 1510.
[http://dx.doi.org/10.3390/biomedicines9111510] [PMID: 34829739]
[6]
Tai S, Zhou Y, Fu L, et al. Dapagliflozin impedes endothelial cell senescence by activating the SIRT1 signaling pathway in type 2 diabetes. Heliyon 2023; 9(8): e19152.
[http://dx.doi.org/10.1016/j.heliyon.2023.e19152] [PMID: 37664712]
[7]
Mone P, Lombardi A, Kansakar U, et al. Empagliflozin improves the MicroRNA signature of endothelial dysfunction in patients with heart failure with preserved ejection fraction and diabetes. J Pharmacol Exp Ther 2023; 384(1): 116-22.
[http://dx.doi.org/10.1124/jpet.121.001251] [PMID: 36549862]
[8]
Dhakal B, Shiwakoti S, Park EY, et al. SGLT2 inhibition ameliorates nano plastics-induced premature endothelial senescence and dysfunction. Sci Rep 2023; 13(1): 6256.
[http://dx.doi.org/10.1038/s41598-023-33086-2] [PMID: 37069192]
[9]
Mone P, Varzideh F, Jankauskas SS, et al. SGLT2 inhibition via empagliflozin improves endothelial function and reduces mitochondrial oxidative stress: Insights from frail hypertensive and diabetic patients. Hypertension 2022; 79(8): 1633-43.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.122.19586] [PMID: 35703100]
[10]
Tsapas A, Karagiannis T, Kakotrichi P, et al. Comparative efficacy of glucose‐lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta‐analysis. Diabetes Obes Metab 2021; 23(9): 2116-24.
[http://dx.doi.org/10.1111/dom.14451] [PMID: 34047443]
[11]
Teo YH, Chia AZQ, Teo YN, et al. The impact of sodium–glucose cotransporter inhibitors on blood pressure: A meta-analysis and metaregression of 111 randomized-controlled trials. J Hypertens 2022; 40(12): 2353-72.
[http://dx.doi.org/10.1097/HJH.0000000000003280] [PMID: 36018229]
[12]
Ren B, Chen M. Effect of sodium-glucose cotransporter-2 inhibitors on patients with essential hypertension and pre-hypertension: A meta-analysis. Ther Adv Endocrinol Metab 2022; 13.
[http://dx.doi.org/10.1177/20420188221142450] [PMID: 36533186]
[13]
Kario K, Okada K, Kato M, et al. 24-hour blood pressure-lowering effect of an Sglt-2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: Results from the randomized, placebo-controlled SACRA study. Circulation 2018; 139(18): 2089-97.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.118.037076] [PMID: 30586745]
[14]
Scholtes RA, van Raalte DH, Correa-Rotter R, et al. The effects of dapagliflozin on cardio‐renal risk factors in patients with type 2 diabetes with or without renin‐angiotensin system inhibitor treatment: A post hoc analysis. Diabetes Obes Metab 2020; 22(4): 549-56.
[http://dx.doi.org/10.1111/dom.13923] [PMID: 31742881]
[15]
Weber MA, Mansfield TA, Alessi F, Iqbal N, Parikh S, Ptaszynska A. Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin–angiotensin system blockade. Blood Press 2016; 25(2): 93-103.
[http://dx.doi.org/10.3109/08037051.2015.1116258] [PMID: 26623980]
[16]
Weber MA, Mansfield TA, Cain VA, Iqbal N, Parikh S, Ptaszynska A. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: A randomised, double-blind, placebo-controlled, phase 3 study. Lancet Diabetes Endocrinol 2016; 4(3): 211-20.
[http://dx.doi.org/10.1016/S2213-8587(15)00417-9] [PMID: 26620248]
[17]
Li M, Yi T, Fan F, et al. Effect of sodium-glucose cotransporter-2 inhibitors on blood pressure in patients with heart failure: a systematic review and meta-analysis. Cardiovasc Diabetol 2022; 21(1): 139.
[http://dx.doi.org/10.1186/s12933-022-01574-w] [PMID: 35879763]
[18]
Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380(24): 2295-306.
[19]
Fletcher RA, Arnott C, Rockenschaub P, et al. Canagliflozin, blood pressure variability, and risk of cardiovascular, kidney, and mortality outcomes: pooled individual participant data from the CANVAS and CREDENCE trials. J Am Heart Assoc 2023; 12(13): e028516.
[http://dx.doi.org/10.1161/JAHA.122.028516] [PMID: 37345834]
[20]
Provenzano M, Toto RD, Vart P. Effect of dapagliflozin on blood pressure in patients with ckd: a pre-specified analysis from DAPA-CKD. Kidney Int Rep 2022; 7(2): S112.
[21]
Herrington WG, Staplin N, Wanner C, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med 2023; 388(2): 117-27.
[http://dx.doi.org/10.1056/NEJMoa2204233] [PMID: 36331190]

Rights & Permissions Print Cite
Article Metrics
13
1
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy